|
Pronunciation |
|
(hal
SIN oh
nide) |
|
|
U.S. Brand
Names |
|
Halog®; Halog®-E |
|
|
Generic
Available |
|
No |
|
|
Pharmacological Index |
|
Corticosteroid, Topical |
|
|
Use |
|
Inflammation of corticosteroid-responsive dermatoses [high potency topical
corticosteroid] |
|
|
Pregnancy Risk
Factor |
|
C |
|
|
Contraindications |
|
Viral, fungal, or tubercular skin lesions, known hypersensitivity to
halcinonide or any component |
|
|
Warnings/Precautions |
|
Adverse systemic effects may occur when used on large areas of the body,
denuded areas, for prolonged periods of time, with an occlusive dressing, and/or
in infants or small children |
|
|
Adverse
Reactions |
|
<1%: Itching, dry skin, folliculitis, hypertrichosis, acneiform eruptions,
hypopigmentation, perioral dermatitis, allergic contact dermatitis, skin
maceration, skin atrophy, striae; local burning, irritation, miliaria; secondary
infection |
|
|
Overdosage/Toxicology |
|
When consumed in excessive quantities, systemic hypercorticism and adrenal
suppression may occur; in those cases, discontinuation and withdrawal of the
corticosteroid should be done judiciously |
|
|
Drug
Interactions |
|
No data reported |
|
|
Mechanism of
Action |
|
Decreases inflammation by suppression of migration of polymorphonuclear
leukocytes and reversal of increased capillary permeability |
|
|
Pharmacodynamics/Kinetics |
|
Absorption: Percutaneous absorption varies by location of topical application
and the use of occlusive dressings
Metabolism: Primarily in the liver
Elimination: By the kidneys |
|
|
Usual Dosage |
|
Children and Adults: Topical: Apply sparingly 1-3 times/day, occlusive
dressing may be used for severe or resistant dermatoses; a thin film of cream or
ointment is effective; do not overuse. Therapy should be discontinued when
control is achieved; if no improvement is seen, reassessment of diagnosis may be
necessary. |
|
|
Mental Health: Effects
on Mental Status |
|
None noted |
|
|
Mental Health:
Effects on Psychiatric
Treatment |
|
None noted |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
No effects or complications reported |
|
|
Patient
Information |
|
A thin film of cream or ointment is effective; do not overuse; do not use
tight-fitting diapers or plastic pants on children being treated in the diaper
area; use only as prescribed, and for no longer than the period prescribed;
apply sparingly in light film; rub in lightly; avoid contact with eyes; notify
physician if condition being treated persists or worsens |
|
|
Nursing
Implications |
|
A thin film of cream or ointment is effective; do not overuse; do not use
tight-fitting diapers or plastic pants on children being treated in the diaper
area; use only as prescribed, and for no longer than the period prescribed;
apply sparingly in light film; rub in lightly; avoid contact with eyes; notify
physician if condition being treated persists or worsens |
|
|
Dosage Forms |
|
Cream (Halog®): 0.025% (15 g, 60 g, 240 g); 0.1% (15 g,
30 g, 60 g, 240 g)
Cream, emollient base (Halog®-E) : 0.1% (15 g, 30 g, 60
g)
Ointment, topical (Halog®): 0.1% (15 g, 30 g, 60 g, 240
g)
Solution (Halog®): 0.1% (20 mL, 60 mL)
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
|